vs
Side-by-side financial comparison of Arcellx, Inc. (ACLX) and Aligos Therapeutics, Inc. (ALGS). Click either name above to swap in a different company.
Arcellx, Inc. is the larger business by last-quarter revenue ($1.7M vs $169.0K, roughly 9.8× Aligos Therapeutics, Inc.). Arcellx, Inc. runs the higher net margin — -3513.4% vs -11763.9%, a 8250.5% gap on every dollar of revenue. On growth, Aligos Therapeutics, Inc. posted the faster year-over-year revenue change (-72.1% vs -89.2%). Over the past eight quarters, Aligos Therapeutics, Inc.'s revenue compounded faster (-50.7% CAGR vs -79.5%).
Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for prevalent liver diseases and viral infections. Its core pipeline includes candidates for chronic hepatitis B, non-alcoholic steatohepatitis, and other liver-related disorders, advancing R&D to serve unmet global patient needs.
ACLX vs ALGS — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $1.7M | $169.0K |
| Net Profit | $-58.1M | $-19.9M |
| Gross Margin | — | — |
| Operating Margin | -3850.2% | -12907.7% |
| Net Margin | -3513.4% | -11763.9% |
| Revenue YoY | -89.2% | -72.1% |
| Net Profit YoY | -23.4% | 75.8% |
| EPS (diluted) | $-1.01 | $4.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.7M | $169.0K | ||
| Q3 25 | $4.9M | $741.0K | ||
| Q2 25 | $7.6M | $965.0K | ||
| Q1 25 | $8.1M | $311.0K | ||
| Q4 24 | $15.3M | $606.0K | ||
| Q3 24 | $26.0M | $1.3M | ||
| Q2 24 | $27.4M | $1.1M | ||
| Q1 24 | $39.3M | $694.0K |
| Q4 25 | $-58.1M | $-19.9M | ||
| Q3 25 | $-55.8M | $-31.5M | ||
| Q2 25 | $-52.8M | $-15.9M | ||
| Q1 25 | $-62.3M | $43.1M | ||
| Q4 24 | $-47.1M | $-82.2M | ||
| Q3 24 | $-25.9M | $-19.3M | ||
| Q2 24 | $-27.2M | $5.1M | ||
| Q1 24 | $-7.2M | $-34.9M |
| Q4 25 | -3850.2% | -12907.7% | ||
| Q3 25 | -1248.3% | -3827.4% | ||
| Q2 25 | -777.4% | -1924.0% | ||
| Q1 25 | -847.6% | -6187.5% | ||
| Q4 24 | -348.2% | -3393.2% | ||
| Q3 24 | -129.1% | -1610.5% | ||
| Q2 24 | -127.8% | -2489.5% | ||
| Q1 24 | -40.3% | -3176.7% |
| Q4 25 | -3513.4% | -11763.9% | ||
| Q3 25 | -1127.1% | -4256.0% | ||
| Q2 25 | -698.6% | -1643.8% | ||
| Q1 25 | -766.0% | 13854.7% | ||
| Q4 24 | -308.4% | -13556.1% | ||
| Q3 24 | -99.4% | -1540.7% | ||
| Q2 24 | -99.3% | 477.0% | ||
| Q1 24 | -18.3% | -5023.5% |
| Q4 25 | $-1.01 | $4.23 | ||
| Q3 25 | $-0.99 | $-3.04 | ||
| Q2 25 | $-0.94 | $-1.53 | ||
| Q1 25 | $-1.13 | $-2.11 | ||
| Q4 24 | $-0.87 | $-13.10 | ||
| Q3 24 | $-0.48 | $-3.07 | ||
| Q2 24 | $-0.51 | $0.81 | ||
| Q1 24 | $-0.14 | $-5.58 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $450.3M | $77.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $402.4M | $53.5M |
| Total Assets | $604.0M | $88.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $450.3M | $77.8M | ||
| Q3 25 | $461.4M | $99.1M | ||
| Q2 25 | $453.1M | $122.9M | ||
| Q1 25 | $543.3M | $137.9M | ||
| Q4 24 | $587.4M | $56.9M | ||
| Q3 24 | $574.3M | $74.9M | ||
| Q2 24 | $516.7M | $94.5M | ||
| Q1 24 | $573.9M | $112.7M |
| Q4 25 | $402.4M | $53.5M | ||
| Q3 25 | $440.8M | $71.8M | ||
| Q2 25 | $392.2M | $101.9M | ||
| Q1 25 | $416.9M | $116.4M | ||
| Q4 24 | $454.8M | $-29.0M | ||
| Q3 24 | $483.0M | $50.1M | ||
| Q2 24 | $487.2M | $67.2M | ||
| Q1 24 | $496.6M | $59.8M |
| Q4 25 | $604.0M | $88.5M | ||
| Q3 25 | $655.9M | $109.8M | ||
| Q2 25 | $619.1M | $134.7M | ||
| Q1 25 | $648.1M | $150.7M | ||
| Q4 24 | $711.3M | $70.1M | ||
| Q3 24 | $764.9M | $88.4M | ||
| Q2 24 | $734.3M | $108.8M | ||
| Q1 24 | $779.7M | $127.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-58.2M | $-21.7M |
| Free Cash FlowOCF − Capex | $-58.9M | — |
| FCF MarginFCF / Revenue | -3563.4% | — |
| Capex IntensityCapex / Revenue | 46.2% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-212.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-58.2M | $-21.7M | ||
| Q3 25 | $-49.2M | $-24.3M | ||
| Q2 25 | $-39.7M | $-15.5M | ||
| Q1 25 | $-63.1M | $-20.9M | ||
| Q4 24 | $-46.0M | $-18.4M | ||
| Q3 24 | $30.7M | $-20.1M | ||
| Q2 24 | $-36.2M | $-19.5M | ||
| Q1 24 | $-31.9M | $-22.7M |
| Q4 25 | $-58.9M | — | ||
| Q3 25 | $-49.5M | — | ||
| Q2 25 | $-40.2M | — | ||
| Q1 25 | $-63.9M | — | ||
| Q4 24 | $-47.5M | — | ||
| Q3 24 | $28.4M | — | ||
| Q2 24 | $-39.5M | — | ||
| Q1 24 | $-38.3M | — |
| Q4 25 | -3563.4% | — | ||
| Q3 25 | -1000.3% | — | ||
| Q2 25 | -532.4% | — | ||
| Q1 25 | -786.4% | — | ||
| Q4 24 | -311.3% | — | ||
| Q3 24 | 109.2% | — | ||
| Q2 24 | -144.1% | — | ||
| Q1 24 | -97.7% | — |
| Q4 25 | 46.2% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 6.4% | — | ||
| Q1 25 | 9.6% | — | ||
| Q4 24 | 9.8% | — | ||
| Q3 24 | 8.8% | — | ||
| Q2 24 | 11.7% | — | ||
| Q1 24 | 16.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -3.85× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
